Rheumatoid Arthritis

  • James R. O'Dell
  • Josef S. Smolen
  • Daniel Aletaha
  • Dwight R. Robinson
  • E. William St. Clair


Rheumatoid arthritis (RA) affects all ethnic groups. Women are nearly three times more likely than men to develop the disease. The pattern of arthritis typically favors distal and symmetrical involvement. The most commonly involved joints are the wrists, metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints. However, many other joints can also be involved. Shoulder, elbow, hip, knee, or neck disease (particularly at the atlanto-axial joint, C1–C2) are frequently observed. Most presentations are subacute in nature, with the insidious onset of fatigue, morning stiffness, and arthritis. More explosive onsets of disease are also described. If untreated, RA is a chronic, progressive disorder that leads to joint damage, disability, and early mortality. A variety of extraarticular features are typical of “seropositive” RA (RA associated with the presence of rheumatoid factor in the serum). These include rheumatoid nodules, secondary Sjögren's syndrome, interstitial lung disease, scleritis, and rheumatoid vasculitis. Approximately 70% of patients with RA are rheumatoid factor positive. An approximately equal percentage has antibodies directed against cyclic citrullinated peptides (i.e., anti-CCP antibodies). There is substantial but not complete overlap between groups of patients who are rheumatoid factor positive and those who have anti-CCP antibodies. Some patients have RA that appears in every way to be typical disease yet do not have either rheumatoid factor or anti-CCP antibodies. These patients are said to have “seronegative RA.” Radiographic studies in RA reveal joint space narrowing, erosions, deformities, and periarticular osteopenia. Treatment approaches now emphasize early interventions designed to suppress joint inflammation entirely as soon as possible after the onset of clinical disease.


Rheumatoid Arthritis Rheumatoid Arthritis Patient Rheumatoid Factor Interstitial Lung Disease Early Rheumatoid Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aletaha D, Nell VPK, Stamm T, et al Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res 2005a; 7:R796–R806CrossRefGoogle Scholar
  2. Aletaha D, Ward MM, Machold KP, et al Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005b; 52:2625–2636CrossRefGoogle Scholar
  3. Aletaha D, Breedveld FC, Smolen JS. The need for new classification criteria for rheumatoid arthritis. Arthritis Rheum 2005c; 52:3333–3336CrossRefGoogle Scholar
  4. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007; 56(10): 3226–3235PubMedCrossRefGoogle Scholar
  5. Arnett FC, Edworthy SM, Block DA, et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315–324PubMedCrossRefGoogle Scholar
  6. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690–1697PubMedCrossRefGoogle Scholar
  7. Avnon LS, Abu-Shakra M, Flusser D, et al Pleural effusion associated with RA Rheum International 2007; 27:919–925CrossRefGoogle Scholar
  8. Axford JS. Rheumatic manifestations of haemochromatosis. Baillieres Clin Rheumatol 1991; 5:351–365PubMedCrossRefGoogle Scholar
  9. Bathon JM, Martin RW, Fleischmann RM, et al A comparison of etan-ercept and methotrexate in early rheumatoid arthritis. N Engl J Med 2000;343:1586–93PubMedCrossRefGoogle Scholar
  10. Bellhorn LR, Hess EV. Erosive osteoarthritis. Semin Arthritis Rheum 1993; 22:298–306CrossRefGoogle Scholar
  11. Boers M, Verhoeven AC, Markusse HM, et al Randomised comparison of combined step-down prednisolone, methotrexate and sulphasala-zine with sulphasalazine alone in early rheumatoid arthritis: A randomised trial. Lancet 1997; 350:309–318PubMedCrossRefGoogle Scholar
  12. Breedveld F, Agarwal S, Yin M, et al Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47:1119–1128PubMedCrossRefGoogle Scholar
  13. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983–989PubMedCrossRefGoogle Scholar
  14. Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 2002; 29:2031–2033Google Scholar
  15. Carter JD, Ladhani A, Ricca LR, et al A safety assessment of tumor necrosis factor antagonists during pregnancy: A review of the Food and Drug Administration database. J Rheumatol 2009; 36:3Google Scholar
  16. Chan MT. Owen P. Dunphy J, et al Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008; 35 (1):77–83PubMedGoogle Scholar
  17. Ching DW, Petrie JP, Klemp P, et al Injection therapy of superficial rheumatoid nodules. Br J Rheumatol 1992; 31:775PubMedCrossRefGoogle Scholar
  18. Choi HK, Hernan MA, Seeger JD, et al Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002; 359(9313):1173–1177PubMedCrossRefGoogle Scholar
  19. Cohen SB, Dore RK, Lane NE, et al Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, doubleblind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58(5):1299–1309PubMedCrossRefGoogle Scholar
  20. De Souza AW, Fernendes V, Ferrari AJ. Female gout: Clinical and laboratory features. J Rheumatol 2005; 32:2186–2188PubMedGoogle Scholar
  21. Doherty M, Dieppe PA. Crystal deposition disease in the elderly. Clin Rheum Dis 1986; 12:97–116PubMedGoogle Scholar
  22. Drossaers-Bakker KW, de Buck M, van Zeben D, et al Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42:1854–1860PubMedCrossRefGoogle Scholar
  23. Fernandez A, Quintana G, Rondon F, et al Lupus arthropathy: A case series of patients with rhupus. Clin Rheumatol 2006; 25:164–167PubMedCrossRefGoogle Scholar
  24. Finckh A, Dehler S, Costenbader KH, et al Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2007; 66:1066–1071PubMedCrossRefGoogle Scholar
  25. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2009 (in press)Google Scholar
  26. Genovese MC, Becker JC, Schiff M, et al Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353(11):1114–1123PubMedCrossRefGoogle Scholar
  27. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, et al Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005; 52:3381–3390PubMedCrossRefGoogle Scholar
  28. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8(1):R29PubMedCrossRefGoogle Scholar
  29. Gonzalez A, Kremers HM, Crowson CS, et al Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis as in non-rheumatoid arthritis patients? Ann Rheum Dis 2006; 67:64–69CrossRefGoogle Scholar
  30. Grigor C, Capell H, Stirling A, et al Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A singleblind randomised controlled trial. Lancet 2004; 364:263–269PubMedCrossRefGoogle Scholar
  31. Harrison BJ, Symmons DP, Barret EM, Silman AS. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 1998; 25(2324):2330.Google Scholar
  32. Hyrich KL, Lunt M, Watson KD, et al Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 2007; 56(1):13–20PubMedCrossRefGoogle Scholar
  33. Kalajian A, Callen J. Multicentric reticulohistiocytosis successfully treated with infliximab: An illustrative case and evaluation of cytokine expression supporting anti-tumor necrosis factor therapy. Arch Dermatol 2008; 144:1360–1366PubMedCrossRefGoogle Scholar
  34. Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Gluco-corticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333:142–146PubMedCrossRefGoogle Scholar
  35. Klareskog L, Stolt P, Lundberg K, et al A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38–46PubMedCrossRefGoogle Scholar
  36. Kobelt G, Jönsson B. The burden of rheumatoid arthritis and access to treatment: Outcome and cost-utility of treatments. Eur J Health Econ 2008; 8 (Suppl 2):S95–S106CrossRefGoogle Scholar
  37. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, et al The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43(8):1831–1835PubMedCrossRefGoogle Scholar
  38. Lee H, Irigoyen P, Kern M, et al Interaction between smoking, the shared eiptope, and anti-cyclic citrullinated peptide: A mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007; 56:1745–1753PubMedCrossRefGoogle Scholar
  39. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002; 50:373–382PubMedCrossRefGoogle Scholar
  40. Lunardi C, Tinazzi E, Bason C, et al Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 2008; 8:116–120PubMedCrossRefGoogle Scholar
  41. Machold KP, Stamm TA, Nell VP, et al Very recent onset rheumatoid arthritis: Clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2006 [Epub 2006 Aug 9 ahead of print]Google Scholar
  42. Masi, AT. Articular patterns in the early course of rheumatoid arthritis. Am J Med 1983; 75:16PubMedCrossRefGoogle Scholar
  43. Mattey DL, Dawes PT, Clarke S, et al Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Care Res 2002; 47:403–407CrossRefGoogle Scholar
  44. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21(5):885–906PubMedCrossRefGoogle Scholar
  45. Mierau M, Schoels M, Gonda G, et al Assessing remission in clinical practice. Rheumatology 2007; 46:975–979 [Epub 2007 Mar 6]PubMedCrossRefGoogle Scholar
  46. Mikuls TR, Huges LB, Westfall AO, et al Cigarette smoking, disease severity, and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis 2008; 67:1529–1534PubMedCrossRefGoogle Scholar
  47. Morozzi G, Bellisai F, Fioravanti A, Galeazzi M. Absence of anti-cyclic citrullinated peptide antibodies in erosive osteoarthritis: Further serological evidence of the disease as a subset of osteoarthritis. Ann Rheum Dis 2005; 64:1095–1096PubMedCrossRefGoogle Scholar
  48. Mottonen T, Hannonen P, Leirisalo-Repo M 1999 et al Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial FIN-RACo trial group. Lancet 353(9164) 1568–1573PubMedCrossRefGoogle Scholar
  49. Nell V, Machold KP, Stamm TA, et al Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64:1731–1736 [Epub 2005 May 5]PubMedCrossRefGoogle Scholar
  50. Nishimura K, Sugiyama D, Kogata Y, et al Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146:797–808PubMedCrossRefGoogle Scholar
  51. O'Dell J. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334:1287–1291PubMedCrossRefGoogle Scholar
  52. O'Dell R. Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis? Drugs 1999; 57:279–282PubMedCrossRefGoogle Scholar
  53. Ostendorf B, Scherer A, Specker C, et al Jaccoud's arthropathy in systemic lupus erythematosus: Differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum 2003; 48:157–165PubMedCrossRefGoogle Scholar
  54. Padyukov L, Silva C, Stolt P, et al A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50:3085–3092PubMedCrossRefGoogle Scholar
  55. Plant MJ, Jones PW, Saklatvala J, et al Patterns of radiological progression in rheumatoid arthritis: Results of an 8 year prospective study. J Rheumatol 1998; 25:417–426PubMedGoogle Scholar
  56. Rantapaa-Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005;34:83PubMedCrossRefGoogle Scholar
  57. Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a doubleblind parallel study of 174 patients. Br J Rheumatol 1997; 36:345–352PubMedCrossRefGoogle Scholar
  58. Rennard SI, Fogarty C, Kelsen S, et al The safety and efficacy of inflix-imab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:926–934PubMedCrossRefGoogle Scholar
  59. Saag KG, Cerhan JR, Kolluri S, et al Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56:463–469PubMedCrossRefGoogle Scholar
  60. Schellekens GA, Visser H, de Jong BA, et al The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155–163.PubMedCrossRefGoogle Scholar
  61. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Arthritis Rheum 1996; 39:732–735PubMedCrossRefGoogle Scholar
  62. Sinclair D, Hull RG. Why do general practitioners request rheumatoid factor? A study of symptoms 2003 requesting patterns and patient outcome Ann Clin Biochem 40(Pt 2) 131–137PubMedCrossRefGoogle Scholar
  63. Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: Aggressive therapy, methotrex-ate, and quantitative measures. Clin Exp Rheumatol 2003a; 21(5 Suppl 31):S209–S210Google Scholar
  64. Smolen JS, Breedveld FC, Schiff MH, et al A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003b; 42:244–257CrossRefGoogle Scholar
  65. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis. Fact or Fiction? Arthritis Rheum 2005; 52:2975–2983PubMedCrossRefGoogle Scholar
  66. Smolen JS, Han C, Van der Heijde DM, et al Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus metho-trexate: The impacts of remission and TNF blockade. Ann Rheum Dis 2009; (6) 823–7CrossRefGoogle Scholar
  67. Smolen J, Kay J, Doyle MK, et al Golimumab, a new human anti-TNF alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2008b; 67(Suppl II):50Google Scholar
  68. Stone JH, Holbrook JT, Marriott MA, et al, for the Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608–1618Google Scholar
  69. Svensson B, Boonen A, Albertsson K, et al Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005; 52:3360–3370PubMedCrossRefGoogle Scholar
  70. Thery C, Lekieffre J, Gosselin B, et al Atrio-ventricular block in rheumatoid polyarthritis. Arch Mal Coeur Vaiss 1974; 67:1181–1191PubMedGoogle Scholar
  71. Turesson C, O'Fallon WM, Crowson CS, et al Extra-articular disease manifestation in rheumatoid arthritis: Incidence, trends, and risk factors over 46 years. Ann Rheum Dis 2003; 62:722–727PubMedCrossRefGoogle Scholar
  72. van der Heijde DM, van Riel PL, van Leeuwen MA, et al Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31(8):519–525PubMedCrossRefGoogle Scholar
  73. van der Helm-van Mil AH, le Cessie S, van Dongen H, et al A prediction rule for disease outcome in patients with recent-onset undif-ferentiated arthritis: How to guide individual treatment decisions. Arthritis Rheum 2007; 56:433PubMedCrossRefGoogle Scholar
  74. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004; 50:709–715PubMedCrossRefGoogle Scholar
  75. van Vollenhoven R. Switching between biological agents. Clin Exp Rheumatol 2004; 22(Suppl 5):S115–S121PubMedGoogle Scholar
  76. van Vugt RM, Derksen RH, Kater L, Bijlsma JW. Deforming arthropa-thy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998; 57:540–544PubMedCrossRefGoogle Scholar
  77. Verstappen SM, Jacobs JW, Heurkens AH, 2007 et al Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66(11)1443–1449PubMedCrossRefGoogle Scholar
  78. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38(9):1261–1265PubMedCrossRefGoogle Scholar
  79. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward NM. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298:187–193PubMedCrossRefGoogle Scholar
  80. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose predniso-lone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:3371–3380PubMedCrossRefGoogle Scholar
  81. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002; 29(9):1851–1857PubMedGoogle Scholar
  82. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586–597PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • James R. O'Dell
    • 1
  • Josef S. Smolen
    • 2
  • Daniel Aletaha
    • 2
  • Dwight R. Robinson
  • E. William St. Clair
    • 3
  1. 1.Department of Internal Medicine OmahaUniversity of Nebraska Medical CenterNebraskaUSA
  2. 2.Department of RheumatologyMedical University of ViennaViennaAustria
  3. 3.Medicine DepartmentDuke University Medical CenterDurhamUSA

Personalised recommendations